Drag

From PCOS to PMOS: Polyendocrine Metabolic Ovarian Syndrome

Marta Aguilar

In practice, we often see the legacy of an excessively gynaecological, reductionist view of polyendocrine metabolic ovarian syndrome (PMOS), previously known as PCOS.

From PCOS to PMOS (polyendocrine metabolic ovarian syndrome)

This is one of the most common conditions affecting women’s health, and the traditional combination of contraceptive pills and weight-loss diets has proved inadequate. Nutrition professionals need to stop treating the uterus as the origin and recognise it as a target of a much more complex systemic process.

Our challenge is to change our mindset and offer a deeper perspective. The paradigm is changing radically; updating our approach is the first step towards meaningful support for patients.

What PMOS really is

Understanding PMOS begins with abandoning the idea of a purely ovarian condition. It is a complex, systemic endocrine-metabolic disorder with strong genetic and epigenetic foundations. 

It is an inherent individual predisposition whose severity and symptoms vary greatly according to the patient’s circumstances. In the same woman, periods of relative latency can alternate with pronounced symptoms. This depends on age-related biological changes, such as naturally declining adrenal androgens, but particularly on metabolic, environmental and behavioural factors we can influence.

PMOS affects everything from energy management to the nervous system. We will examine its key aspects to support a comprehensive clinical approach.

Causes and triggers

PMOS has no single direct cause. To identify our scope for intervention, distinguish three levels: the primary cause, or bullet; neuroendocrine triggers, which pull the trigger; and systemic aggravating factors, which amplify the effect.

Primary causes

Primary causes are the biological starting conditions. Without this foundation, a patient will not develop PMOS. 

  • Inherited predisposition and ethnicity

Individuals are born with documented genetic susceptibility, particularly prevalent among Hispanic women. Without this genetic signature, environmental factors alone do not produce the syndrome.

  • Prenatal programming

Exposure in the womb to elevated maternal androgens or placental dysfunction can alter fetal gene expression, programming hormonal and metabolic axes before birth.

Neuroendocrine triggers of PMOS

These environmental factors directly interact with the central nervous system and hormone receptors, activating or worsening genetic predisposition. They include:

  • Chronic stress, excessive demands and allostatic load

Our bodies are not biologically designed for a hyperproductive lifestyle. Sustained work demands, work–life pressures, poor rest, overtraining or unrecognised energy restriction keep the body in a constant state of threat. 

This often-unnoticed physical or mental strain affects the hypothalamus through cortisol and corticotropin-releasing hormone (CRH), altering gonadotropin-releasing hormone (GnRH) pulses and driving adrenal androgen production (DHEA-S), commonly seen in adolescents and young women.

  • Exposure to endocrine disruptors

Everyday chemicals in food containers and bottles (bisphenols), conventional cosmetics (phthalates) and food pesticides resemble hormones sufficiently to bind cellular receptors. They can inhibit aromatase activity in ovarian tissue. Blocking this enzyme interrupts androgen-to-oestrogen conversion, creating an androgen-rich ovarian environment and slowing normal follicular development. 

  • Habits disrupting circadian rhythms

Shift work, social jet lag and night-time blue light disrupt physiological melatonin and cortisol peaks, perpetuating central neuroendocrine dysregulation.

Metabolic amplifiers of PMOS

These factors add fuel to the fire. Unlike neuroendocrine triggers, they do not directly mislead receptors or alter the hypothalamus; instead, they change the environment in which hormones operate, amplifying the syndrome:

  • Mismatch between dietary glycaemic load and metabolic tolerance

Genetically based insulin resistance can markedly lower carbohydrate tolerance. Inactivity further reduces muscle insulin sensitivity, so an apparently healthy carbohydrate intake may overload some women with PMOS. Insulin-driven androgen amplification is therefore not limited to diets rich in ultra-processed foods or refined sugars. 

The pancreas compensates by producing more insulin. This compensatory hyperinsulinaemia affects the body through two pathways: 

  1. Increased testosterone production. High insulin directly stimulates ovarian theca cells, enhancing LH action and excessive testosterone production.
  2. Reduced transport in blood. The liver produces sex hormone-binding globulin (SHBG) to bind and transport testosterone safely. High insulin reduces SHBG production, increasing free, active testosterone. We will revisit this under blood tests.
  • Obesity and dysfunctional adiposity

Although obesity does not cause PMOS, it is its strongest amplifier. Visceral fat releases free fatty acids and inflammatory adipokines that block insulin receptors and worsen peripheral resistance. A woman at normal weight can have PMOS, but additional visceral fat creates ongoing inflammation that worsens androgenic symptoms. 

  • Gastrointestinal dysbiosis

Chronic stress, inactivity, medications such as antibiotics or contraceptives, and diets low in fermentable fibre and high in ultra-processed foods directly damage the intestinal ecosystem. 

Reduced microbial diversity weakens the intestinal barrier, allowing lipopolysaccharides (LPS) into circulation. This metabolic endotoxaemia increases low-grade inflammation and reduces short-chain fatty acids (SCFAs), worsening insulin resistance throughout the body.

Neuroendocrine pathophysiology

PMOS involves a loss of central synchronisation. Understanding this requires reviewing the hypothalamic–pituitary–gonadal (HPG) axis:

  • Hypothalamus: Releases GnRH in pulses into portal circulation.
  • Anterior pituitary: Receives GnRH and stimulates bihormonal gonadotroph cells.
  • LH and FSH release: Gonadotroph output depends on GnRH pulse frequency. Slow pulses favour follicle-stimulating hormone (FSH); rapid pulses favour luteinising hormone (LH).
  • Ovary: LH and FSH travel through blood and stimulate ovarian cells to produce oestradiol, progesterone and androgens, mainly testosterone and androstenedione.

The neuroendocrine triggers described above disrupt this axis. 

In PMOS, GnRH pulses become abnormally rapid and continuous, favouring excessive LH and reduced FSH synthesis. Clinically, this appears as the familiar reversal of the LH/FSH ratio.

What does this imbalance actually do in the ovary?

  1. Chronically excessive LH overstimulates androgen-producing theca cells in the follicle’s outer layer.
  2. Meanwhile, relatively low FSH understimulates granulosa cells surrounding the egg and supporting maturation. They cannot express enough aromatase to convert androgens into oestrogens.

The resulting androgen-rich ovarian environment blocks optimal follicular maturation. This helps explain poor oocyte quality or underlying fertility difficulties even when cycles appear regular and ovulatory.

In many patients, a feedback loop develops. Circulating androgens return to the central nervous system and can produce hypothalamic progesterone resistance. Progesterone normally increases after ovulation and slows GnRH pulses. Resistance removes this modulation, maintaining rapid pulses chronically.

Hyperandrogenism becomes both a consequence and a perpetuating factor. A persistent loop is not necessarily irreversible, but the body will not escape it unaided. Our clinical challenge is to interrupt it; later sections examine useful tools. 

Clinical manifestations

Neuroendocrine imbalance and the androgenic environment produce a heterogeneous range of metabolic, dermatological and reproductive signs:

1. Menstrual and ovulatory disturbances

Three scenarios are common:

  • Oligomenorrhoea: Markedly long cycles, over 35 days, the most common pattern.
  • Secondary amenorrhoea: Complete absence of menstruation for more than 3 consecutive months.
  • Polymenorrhoea and complex patterns: Short cycles with two bleeding episodes in one month, caused by oestrogen dips in follicles that begin but fail to complete ovulation.

Although PMOS is the leading cause of anovulatory infertility, it does not mean ovulation never occurs. Many patients ovulate, but follicles take longer to complete maturation and the ovulatory window shifts.

2. Clinical hyperandrogenism and skin manifestations

Excess free testosterone and androstenedione affect pilosebaceous-unit receptors. Consultations can assess: 

  • Hirsutism: Terminal hair in androgen-sensitive areas such as the abdominal midline, chin and chest. A total modified Ferriman–Gallwey score of 6 or more supports this assessment (link).
  • Acne and androgenic alopecia: Diffuse hair thinning in a female distribution, including a widening central part.
  • Premature adrenarche: Pubic or underarm hair or body-odour changes before age 8, indicating intrinsic adrenal hyperactivity from childhood.

3. Metabolic inflexibility and body composition

PMOS affects adipose tissue and mitochondrial function, producing two interconnected manifestations:

  • Metabolic inflexibility: Chronic mitochondrial dysfunction prevents efficient switching between fuels. During running, this means glycogen dependence even at low intensity, premature fatigue and increased risk of hitting the wall.
  • Central adiposity (lean PCOS): Hyperandrogenism redistributes fat towards the viscera, producing an apple-shaped pattern. Even with normal BMI, persistent subcutaneous fat and increased waist circumference can indicate low-grade inflammation and insulin resistance.

Diagnosis and exclusion criteria

The evolution of a confusing diagnosis

Diagnosis is often the first difficulty. Decades of debate over classification help explain why patients receive conflicting assessments from different gynaecologists. 

This reflects a historically inconsistent perspective and changing criteria rather than individual professional failings. Three main criteria sets emerged: 

  • 1990 NIH criteria: A rigid focus on ovulatory disturbances, including oligo-/amenorrhoea, and clinical hyperandrogenism.
  • 2003 Rotterdam criteria: Added important nuance and transvaginal ultrasound, introducing combinations intended to capture symptom diversity.
  • AE-PCOS Society criteria: Made hyperandrogenism essential, requiring coexisting ovarian dysfunction, polycystic morphology or both.

From PCOS to PMOS: why the name change reflects physiology

The turning point came in May 2026. After 14 years of international collaboration, surveys involving thousands of professionals and support from over 50 scientific societies, a consensus in The Lancet (link) officially replaced PCOS with PMOS, polyendocrine metabolic ovarian syndrome.

This is more than a new acronym: it addresses two historical limitations and brings criteria into a unified global framework.

The paradigm shift rests on four pillars: 

1. Moving beyond cysts and reproductive organs

The historical word “polycystic” understandably made patients fear that cysts or dangerous masses were required for diagnosis. 

The new name better reflects cellular physiology because these are not cysts. Ultrasound shows accumulated follicles whose normal development has been interrupted, and this does not occur in every case.

Removing the misleading name shifts the ovary from the supposed origin to a target organ affected by deeper endocrine dysfunction.

2. A comprehensive approach prioritising metabolic and endocrine roots

“Polyendocrine” and “metabolic” challenge the purely gynaecological framing that has dominated for decades.

Peripheral insulin resistance, compensatory hyperinsulinaemia and low-grade inflammation are central to the problem rather than secondary consequences. 

We now shift our primary attention from the uterus to the metabolic system to regulate endocrine function. 

3. Changing treatment: from contraceptive pills to lifestyle

Historically, treatment often meant oral contraception to artificially regulate cycles. Contraceptives have a legitimate clinical role under medical supervision, but withdrawal bleeding must not mask symptoms while underlying endocrine dysfunction is ignored.

The new consensus changes the approach fundamentally. Now personalised nutrition therapy, energy management and strength training are established as first-line medical therapy. This is not professional bias: rigorous international guidance, such as the Monash International Consensus, gives nutrition and exercise a Class I recommendation (Level A evidence).

Our challenge is to improve ovarian function by restoring insulin sensitivity and metabolic flexibility through lifestyle. 

4. Reducing diagnostic delays

Rigid traditional criteria left around 70% of affected women facing years of delay. Attention often arrived only after periods stopped or conception proved difficult. 

The broader endocrine framework offers nutrition professionals tools to identify warning signs earlier. 

These include the modified Ferriman–Gallwey scale for terminal hair, visual insulin-resistance signs such as acanthosis nigricans in skin folds, and metabolic tests such as HOMA-IR or LH/FSH ratio, even in regularly ovulating patients.

Current PMOS diagnostic criteria

Formal diagnosis still requires at least 2 of the 3 classic clinical pillars (Rotterdam criteria). The methodological change is interpreting them within an endocrine framework rather than separately.

Nutrition professionals should carefully examine these three assessment areas:

  • Hyperandrogenism: Excess androgens assessed through two independent pathways:
    • Clinical: Severe acne, androgenic alopecia or hirsutism. A modified Ferriman–Gallwey score ≥6 is indicative in Mediterranean populations.
    • Biochemical: Elevated total testosterone, free testosterone, free androgen index (FAI) or dehydroepiandrosterone sulphate (DHEA-S).
  • Ovulatory disturbances: Mainly oligomenorrhoea, with cycles over 35 days, or secondary amenorrhoea lasting more than 3 months. Always perform a differential diagnosis to exclude functional hypothalamic amenorrhoea (FHA).
  • Polycystic ovarian morphology on ultrasound: At least 12 follicles measuring 2–9 mm in one ovary, or ovarian volume over 10 ml. Follicle numbers and volume naturally decline after age 40.

The four PMOS phenotypes

Combining these criteria produces four phenotypes:

Phenotype Hyperandrogenism (clinical/biochemical) Ovulatory dysfunction (cycles) Ultrasound morphology (follicles)
A – Complete YES YES YES
B – Classic (without ultrasound findings) YES YES NO
C – Ovulatory YES NO YES
D – Non-androgenic NO YES YES

Phenotype D describes irregular cycles and retained follicles with normal androgens and no clinical androgenic signs. It carries the greatest risk of underdiagnosis.

Distinguishing phenotypes is essential because metabolic comorbidities, ovulatory dysfunction and the origin of hyperandrogenism differ substantially.

Metabolic vs non-metabolic PMOS

Beyond phenotype labels, identifying whether metabolism drives PMOS or is largely uninvolved defines our scope for intervention. It shows how strongly to prioritise metabolic improvement or whether another approach is required. Two profiles can be distinguished:

  • Metabolic PMOS

Metabolic context drives or directly aggravates the syndrome, with marked insulin resistance and reduced metabolic flexibility. Correcting this environment is the priority. 

History and blood tests commonly reveal:

  • Blood tests: Fasting hyperinsulinaemia, HOMA-IR >2.5, elevated homocysteine and markedly reduced SHBG, increasing free androgens. Free testosterone and androstenedione rise, alongside an altered LH/FSH ratio.
  • Clinical findings and anthropometry: Central adiposity, waist circumference >88 cm, rising BMI and acanthosis nigricans are common. Bleeding is often anovulatory and heavy because of increased peripheral aromatisation in fat tissue.
  • Other factors: Circadian disruption and changes in gut microbiota frequently contribute.
  • Non-metabolic PMOS

This includes the 20–30% of patients with predominantly adrenal origins and intrinsic adrenal hyperactivity often apparent from puberty. “Non-metabolic” avoids incorrectly attributing causation to insulin.

  • Blood tests: Fasting insulin and HOMA-IR are optimal. Androstenedione and LH/FSH can still be elevated, but the distinguishing marker is markedly raised DHEA-S (dehydroepiandrosterone sulphate).
  • Clinical findings and anthropometry: Usually normal BMI, good muscle mass and clinical hyperandrogenism, with noticeably lighter anovulatory bleeding.
  • Differential diagnosis: Carefully exclude non-classic congenital adrenal hyperplasia and functional hypothalamic amenorrhoea.
  • Stress response. Biological responsiveness to stress is often greater.
  • Other factors. Circadian and microbiota disruption may occur as in metabolic PMOS, alongside increased stress reactivity and an overactive HPA axis.

Assuming every case involves insulin resistance is a clinical mistake. Generic advice in non-metabolic PMOS or phenotype D can raise cortisol and perpetuate hormonal dysfunction.

The myth of cysts

“Polycystic” was clinically imprecise and often led athletes to imagine actual cysts or abnormal lumps obstructing the ovary. Ultrasound findings tell a different story. 

Women are born with a finite reserve of approximately one million oocytes in primordial follicles. By puberty, around 400,000–500,000 remain. Only about 400–500 ovulate during reproductive life; the remainder degenerate through apoptosis and ageing.

New oocytes cannot be generated, and the reserve ages continuously whether menstruation occurs or not. Pregnancy, contraception and amenorrhoea do not halt its decline. Oxidative load, cellular damage and smoking accelerate ageing and can bring menopause forward.

Each cycle recruits follicles for initial maturation. FSH then activates antral maturation. Several compete, but usually only the dominant follicle fully matures, ruptures and releases its egg. The others undergo apoptosis. 

Ultrasound shows immature follicles trapped during maturation, not cysts. High LH relative to FSH prevents full maturation but also normal degeneration. They must reach a certain developmental stage for apoptosis and reabsorption; disrupted signalling interrupts this process and follicles accumulate.

Retained follicles are a diagnostic sign rather than a direct danger. They may appear on one scan and disappear on the next because a subsequent hormonal stimulus enables enough development for apoptosis and natural removal. 

Unlike endometriosis, in which ectopic tissue can invade and damage ovarian structure, PMOS involves interrupted normal follicular development.

Blood tests: which biomarkers matter?

Absolute laboratory reference ranges can be insufficient. Our aim is to understand biochemical trends rather than issue a medical diagnosis.

Trends reveal how the athlete’s body functions, how it responds to training or stress, and how nutrition may improve function.

Focus on the following markers:

1. Androgen levels

Androgens originate in different tissues. Their relative sources help identify the focus: 

  • Total and free testosterone:

Blood testosterone >50 ng/dL points towards ovarian involvement. 

The ovary directly produces around 60% of total testosterone, while the adrenal gland produces about 5%.

  • DHEA-S (dehydroepiandrosterone sulphate):

Values in the upper third of the age-specific range or clearly elevated suggest adrenal activity is dominant. 

More than 95% of DHEA-S is produced exclusively in the adrenal glands. 

This indicates links with polygenic inheritance, ACTH stimulation and high biological stress reactivity.

  • Androstenedione:

Less conclusive because around 60% originates in the ovary and 35% in the adrenal gland. 

Values >2.7 ng/ml confirm hyperandrogenism but do not identify its leading gland.

Even when blood results are unclear, calculate the free androgen index (FAI): 

(Total testosterone (nmol/L) / SHBG (nmol/L)) × 100

A result >4.5 confirms biochemical hyperandrogenism.

2. SHBG (sex hormone-binding globulin)

Laboratory ranges are broad, commonly 40–120 nmol/L, but clinically we seek an optimal range of 80–120 nmol/L. 

Higher SHBG leaves fewer free sex hormones circulating to affect tissues.

Nutrition can influence this value, but it cannot be assessed reliably during oral contraceptive use.

3. Anti-Müllerian hormone (AMH)

AMH helps differentiate PMOS from FHA after age 20; levels are physiologically high during puberty. 

PMOS commonly involves elevated AMH (>3.4–4 ng/ml), which aggravates hyperandrogenism by inhibiting granulosa-cell aromatase and blocking FSH effects.

AMH does not validly measure actual ovarian reserve in PMOS because the condition substantially distorts it.

4. Gonadotropin balance (LH/FSH ratio)

A pattern of LH exceeding FSH, especially a ratio >2, indicates ongoing theca-cell stimulation and androgen production.

Prefer tests from the early follicular phase, cycle days 3–5. 

5. Fasting insulin and metabolic profile: 

Glucose is an unreliable metabolic-health marker in PMOS because normal levels may be maintained by pancreatic overwork. HOMA is useful but can appear normal despite underlying hyperinsulinaemia. 

Fasting insulin is the most useful marker for diagnosis and follow-up, ideally measured at baseline and annually. It indicates metabolic impact and progress in managing hyperinsulinaemia. 

Seek fasting insulin below 7–8 u/ml. Higher values indicate active ovarian stimulation, increased androgens and restricted follicular maturation. Assess fasting insulin independently of formally diagnosed insulin resistance, including possible slow hormone clearance. 

Distinguishing metabolic from non-metabolic PMOS defines the influence achievable through nutrition. 

Managing PMOS: lifestyle as first-line therapy

Counting macros is insufficient without first stabilising circadian rhythms and muscle mass. 

Lifestyle influences disease expression, but priorities differ by profile: 

  • In non-metabolic, adrenal PMOS, prioritise chronobiology and rest to reduce central HPA-axis stress.
  • In metabolic PMOS, strength training is fundamental to restoring insulin sensitivity.

Chronobiology and the HPA axis

Rest and ovarian function are closely linked. The hypothalamus responds to stress and its biological clock is often disrupted in PMOS. A review by Anderson (2024) in Frontiers in Bioscience describes marked flattening of nocturnal melatonin, normally peaking around 3–4 a.m., alongside persistently elevated cortisol.

Circadian disruption acts through three pathways: 

  • GnRH disruption:

Short or irregular sleep overstimulates the HPA axis. Excess cortisol accelerates GnRH pulses, driving LH production at the expense of FSH.

  • The melatonin–insulin relationship:

Melatonin concentrates in follicular fluid to protect oocytes from oxidative stress. Insufficient melatonin worsens oocyte quality and peripheral insulin resistance.

  • Morning amplification of 11β-HSD1

Circadian imbalance increases morning 11β-HSD1 activity in fat. This reactivates cortisol locally in visceral tissue, explaining aggravated early-morning insulin resistance and inflammation.

Cortisol and melatonin rhythms in women with PMOS: polyendocrine metabolic ovarian syndrome

What can we do? Begin with routines rather than supplements, which are ineffective when schedules are chaotic:

  • Chrononutrition: Move dinner earlier, reduce its digestive load and avoid caffeine in the second half of the day.

Core temperature must fall for deep sleep. Large or late dinners maintain digestion and temperature, fragmenting sleep.

  • Sleep hygiene: Reduce blue-light exposure before bed, substituting reading, meditation or a warm bath. Keep the bedroom dark, cool and quiet, and seek morning daylight when possible.

Once these foundations are addressed, supplements may provide additional support, as discussed later. 

Strength training and muscle mass

While chronobiology calms the central nervous system, strength training and muscle mass are key to addressing PMOS-related metabolic and inflammatory dysfunction.

In metabolic profiles, inflammation and visceral fat impair insulin receptors, amplifying clinical expression in 7–8 out of 10 women.

Traditional carbohydrate restriction can be risky, especially in athletes, because low energy availability further stresses the HPA axis. Enhancing the tissue that uses glucose is part of the solution. 

Muscle contraction activates AMPK, moving GLUT4 transporters to cell surfaces. Muscle can then take up circulating glucose immediately without insulin involvement.

More active muscle increases mitochondrial numbers and glycogen storage, supporting metabolic flexibility.

Lower insulin restores hepatic SHBG production, binding excess androgens and removing stimulation for ovarian testosterone overproduction.

Comprehensive nutritional management: beyond macros

Success involves foods that modulate insulin and androgens, rather than simply counting macronutrients. 

Managing glycaemic load

Effective glycaemic-load management is central. The key is carbohydrate timing, especially in active women, rather than elimination. 

Automatically replacing bread or cereals with vegetables or tubers can impair performance, deplete glycogen and perpetuate HPA dysfunction through low energy availability.

Precision management has two pillars:

  • Synergy on the plate: Rice and bread need not be banned. Combine them with fibre, healthy fats and protein to slow gastric emptying and lower the meal’s overall glycaemic impact, turning a sharp insulin spike into a manageable curve.
  • Flexibility by carbohydrate type: Choose lower-impact options such as intact whole grains, pulses or cooked-and-cooled tubers containing resistant starch during less active periods. Reserve rapidly absorbed carbohydrates for immediately after training, when GLUT4 translocation supports glucose uptake.

Modulating the food matrix rather than restricting intake reduces pancreatic stress and the ovarian stimulus for excess testosterone, while maintaining performance. 

Manual planning can be time-consuming. INDYA simplifies strategic food-group distribution, macronutrient proportions per meal, carbohydrate portions and total daily fibre. 

Nutrition periodisation: integrating this into INDYA

Scheduling training sessions lets us align carbohydrates with exercise. The software adjusts carbohydrate amounts throughout the day and around workouts, making use of muscle glucose uptake without insulin. 

Protein, fibre and hormones

Isolated carbohydrates raise blood glucose and trigger substantial insulin release. Protein and fibre provide a metabolic counterweight to compensatory hyperinsulinaemia. 

Fibre slows gastric emptying and intestinal sugar absorption, smoothing the glucose curve. A breakfast with 5–10 g fibre, 10–15 g protein and fluid can improve appetite regulation. Studies suggest satiety may unconsciously reduce daily intake by up to 200 kcal.

Raising protein’s share of calories supports muscle and stimulates intestinal peptides such as CCK and GLP-1, improves satiety, increases post-meal thermogenesis and limits excessive insulin stimulation of ovarian theca cells.

Healthy fats and SHBG synthesis

Low SHBG increases free sex hormones, although visible acne, hair growth or hair loss may be absent. SHBG is a useful indicator of hepatic and metabolic health. 

Chronically high insulin reduces hepatic SHBG production. Quality fats do not magically raise it; they support liver cells through two complementary pathways:

  • Direct genetic activation: Polyunsaturated fatty acids, particularly omega-3, bind hepatic receptors to reactivate SHBG gene expression.
  • Cell membrane repair: Polyunsaturated and monounsaturated fats, including extra virgin olive oil and avocado, restore hepatic membrane fluidity and improve impaired insulin-receptor function.

Healthy fats help restore liver insulin sensitivity. As pancreatic demand and fasting insulin fall, the liver can produce SHBG to bind excess free hormones and restore balance.

Managing acne in PMOS

Acne reflects hyperandrogenism through four reinforcing mechanisms: increased sebum, pore keratinisation, skin bacterial dysbiosis and inflammation-related structural damage.

Small dietary changes can address three triggers: 

  • Prioritise full-fat over skimmed dairy: Removing fat markedly increases the insulinotropic response and stimulation of insulin and IGF-1, which promote sebum, making skimmed dairy undesirable in PMOS.
  • Watch sugars and glycaemic load: Refined carbohydrates or poorly managed load raise insulin, activating mTORC1, blocking pores and increasing skin oil.
  • Reduce pro-inflammatory saturated fats: Excess poor-quality fat thickens sebum and facilitates infection.

Three evidence-supported foods: Ceylon cinnamon, apple cider vinegar and ground seeds

These three tools are easy to include in daily meals, with personalised incorporation through INDYA. 

Ceylon cinnamon

Methylhydroxychalcone polymers mimic insulin, improving receptor signalling and glucose entry into muscle. A teaspoon daily supports insulin sensitivity.

Choose Ceylon cinnamon for its liver safety. 

Apple cider vinegar

Acetic acid temporarily inhibits disaccharidases, the intestinal carbohydrate-digesting enzymes, and delays gastric emptying. A tablespoon diluted in water 10–15 minutes before the highest-carbohydrate meal reduces the post-meal glucose peak by up to 30%, easing pancreatic demand.

Ground seed protocol

Clinical evidence supports 30 g ground flaxseed daily for 12 weeks, for example in porridge or yoghurt. Trials report reductions in HOMA-IR, fasting insulin, triglycerides, CRP and leptin, with improved adiponectin.

Grinding is essential: intact seeds’ outer layers prevent nutrient absorption and they pass through unchanged. 

Clinically targeted supplementation for PMOS

Supplements should never be prescribed blindly. Each needs a reason and a specific physiological target reflecting the patient’s context.

Metabolic targets: myo-inositol and berberine

The aim is improved peripheral insulin sensitivity and restored ovarian FSH signalling.

Inositol

It acts as a cellular second messenger. Hyperinsulinaemia increases follicular conversion of myo-inositol (MI) to D-chiro-inositol (DCI), impairing egg maturation. Prioritising MI helps restore the ratio.

Tip: Nuts and seeds support endogenous inositol through phytic acid.

Protocol: 2 g/day powdered myo-inositol for at least 3 months. Useful for irregular cycles when basic follicular responsiveness remains; ineffective in severe pituitary amenorrhoea. 

Berberine (Berberis aristata): 

Like metformin, it activates AMPK, with differences. Metformin strongly suppresses hepatic glucose production, while berberine improves peripheral muscle sensitivity, insulin-receptor expression and glucose uptake. It also inhibits PCSK9, reducing triglycerides and LDL, and directly reduces ovarian inflammation and androgen-producing enzyme activity.

Protocol: 500 mg with meals, 2–3 times daily. Because it can cause constipation, two days off weekly, such as weekends, may reduce costs and cellular adaptation and improve adherence. 

Androgenic and inflammatory targets: zinc, resveratrol and omega-3

The aim is to limit excess androgen production and support corpus luteum function.

Zinc

A progesterone-supporting mineral for cycle balance, with highly individual responses. 

Doses above 15 mg/day can cause stomach discomfort. 

Always take with a main meal, not on an empty stomach, to avoid nausea. Avoid simultaneous high-dose calcium, iron, coffee or tea. Monitor copper if continued beyond 3 months because of absorption competition.

Resveratrol

An endocrine modulator as well as an antioxidant, it inhibits ovarian theca-cell CYP17A1 expression and the key androgen-producing enzyme. It targets biochemical hyperandrogenism and activates SIRT1 sirtuins, improving insulin sensitivity. 

Its effect depends on continued intake; benefits disappear when stopped. 

Protocol: 100–200 mg/day trans-resveratrol, the active, more bioavailable form. Because absorption is low and metabolism rapid, divide into two daily doses with fat-containing meals. Clinical treatment commonly lasts 3 months before reassessing blood results.

Neuroendocrine and HPA targets: ashwagandha, melatonin and magnesium

These aim to reduce adrenal overstimulation, regulate cortisol and protect follicles from oxidative stress.

Ashwagandha:

Ashwagandha is an adaptogen supporting chronic-stress regulation, reducing fasting cortisol and calming the HPA axis to protect the cycle.

Protocol: 600–1,200 mg/day, using KSM66 standardised to 5% active ingredient. 

Weekend breaks can reduce adaptation and treatment cost.

Melatonin:

It synchronises circadian rhythms and provides powerful antioxidant protection within ovarian follicles, improving oocyte quality.

Protocol: 0.3–1 mg/day is sufficient for regulating the biological clock. 

Melatonin temporarily worsens glucose utilisation, so taking it immediately after a large late dinner is inappropriate. Ideally take it 9 hours before waking. Morning fatigue suggests circulating melatonin remains and the dose or timing needs adjustment.

Magnesium bisglycinate:

It calms the central nervous system, reduces chronic stress effects and improves deep sleep.

Protocol: 300–400 mg elemental magnesium daily, preferably at night for muscular and central relaxation.

HPG-axis targets: Vitex agnus-castus and Rhodiola rosea

The aim is to restore communication between brain and ovary when cycles are disrupted.

Vitex (Vitex agnus-castus)

Vitex binds pituitary dopamine receptors, suppressing stress-related prolactin and regulating LH pulses. It can support follicular maturation and progesterone, restoring absent cycles or lengthening short luteal phases. It may help highly irregular PCOS, but evidence is limited and it has no metabolic or insulin effect.

Protocol: 300–400 mg/day standardised dry extract, containing 0.5–0.6% agnusides, taken fasting in the morning for at least 2–3 months.

It is contraindicated with already-high LH, a common severe PMOS pattern, because it may worsen ovulatory blockage. Consider only with normal/low LH and relatively high prolactin.

Rhodiola rosea

This adaptogen improves physical and mental stress resilience. By reducing the brain’s perception of exercise or daily life as constant threats, it helps GnRH pulses regain their natural rhythm and supports ovulation.

Protocol: 200–400 mg/day dry extract, standardised to 3% rosavins and 1% salidrosides.

As with other adaptogens, weekend breaks may reduce receptor tolerance and optimise treatment.

Conclusion

Moving from PCOS to PMOS represents a clinical shift that gives nutrition professionals a central role in treatment. 

Integrating this neuroendocrinology into everyday practice can feel overwhelming, but INDYA’s software helps translate the science into practical, precise and transformative plans.

References

  • Teede H, Khomami M, Morman R et al.
    Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process
    The Lancet, 2026; 407, 2329-2339  – https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext
  • Priya, M. R., Nanthini, A., & Bini, K. P. (2019). Polycystic ovary syndrome: An updated review. International Journal of Health & Allied Sciences, 8(4), 229
  • Stańczak, Natalia Anna, Ewelina Grywalska, and Ewa Dudzińska. “The latest reports and treatment methods on polycystic ovary syndrome.” Annals of medicine 56.1 (2024): 2357737
  • Melis, G. B., Orrù, M., Marotto, M. F., Pilloni, M., Perseu, M., Lello, S., & Paoletti, A. M. (2011). Use of oral contraceptives in the management of acne. Open Access Journal of Contraception, 2, 151-159.
  • Yesiladali, Mert, et al. “Differentiating Polycystic Ovary Syndrome from Adrenal Disorders.” Diagnostics 12.9 (2022): 2045.
  • Bai, Hai, Huanhuan Ding, and Mingming Wang. “Polycystic ovary syndrome (PCOS): symptoms, causes, and treatment.” Clinical and Experimental Obstetrics & Gynecology 51.5 (2024): 126.
  • Chang, Kai-Jung, Jie-Hong Chen, and Kuo-Hu Chen. “The pathophysiological mechanism and clinical treatment of polycystic ovary syndrome: A molecular and cellular review of the literature.” International journal of molecular sciences 25.16 (2024): 9037.
  • Houston, Emma J., and Nicole M. Templeman. “Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS.” Journal of Endocrinology 265.2 (2025).
  • Panidis, D., Tziomalos, K., Misichronis, G., Papadakis, E., Betsas, G., Katsikis, I., & Macut, D. (2012). Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Human reproduction, 27(2), 541-549.
  • Anderson, George. “Polycystic ovary syndrome pathophysiology: integrating systemic, CNS and circadian processes.” Frontiers in Bioscience-Landmark 29.1 (2024): 24.
  • Spinedi, Eduardo, and Daniel P. Cardinali. “The polycystic ovary syndrome and the metabolic syndrome: a possible chronobiotic-cytoprotective adjuvant therapy.” International journal of endocrinology 2018 (2018).
  • Senthilkumar, Harshini, and Mohanapriya Arumugam. “Gut microbiota: a hidden player in polycystic ovary syndrome.” Journal of translational medicine 23.1 (2025): 443.
  • Phylactou, M., Clarke, S. A., Patel, B., Baggaley, C., Jayasena, C. N., Kelsey, T. W., … & Abbara, A. (2020). Clinical and biochemical discriminants between Functional Hypothalamic Amenorrhoea (FHA) and Polycystic Ovary Syndrome (PCOS). Clinical Endocrinology.
  • Tripathi, S., Singh, M., Jain, M., & Khatoon, S. (2020). Nutritional Perspective of Polycystic Ovarian Syndrome: A Review Study. Current Medicine Research and Practice.
  • Simha, A., & Agarwal, S. (2019). Nutrition Education Intervention for the Management of Polycystic Ovary Syndrome (PCOS). Medico-legal Update, 19(2), 21-27.
  • Jiang, Xiaomei, et al. “Effect of light fasting diet therapy on lipid metabolism and sex hormone levels in patients with polycystic ovary syndrome combined with infertility.” Gynecological Endocrinology 41.1 (2025): 2458084.
  • Zhang, Si-wei, et al. “Effect and mechanism of berberine against polycystic ovary syndrome.” Biomedicine & Pharmacotherapy 138 (2021): 111468.
  • Banting, Lauren K., et al. “Physical activity and mental health in women with polycystic ovary syndrome.” BMC women’s health 14.1 (2014): 51.

Te puede interesar

Cómo plantear un menú sin gluten para deportistas

How to Design a Gluten-Free Meal Plan for Athletes

There is a myth that without traditional carbohydrate sources, such as wheat pasta or bread, performance will plummet. In reality, however, it is perfectly possible to compete at the highest level without consuming a single gram of gluten.
intervals e INDYA

INDYA integrates with Intervals.icu: training and nutrition connected

The integration allows INDYA to incorporate information from workouts recorded in Intervals.icu, such as training time, estimated energy expenditure and the effort level of each session. This data can then be used alongside the athlete’s training history to personalize their nutritional plan.
Pliegues cutáneos: medición e interpretación

Skinfolds: Measuring and Interpreting Body Fat

Skinfold measurement is one of the most widely used tools in anthropometry for assessing body composition and monitoring a patient's or athlete's progress.